IL172937A0 - Pyrimidine derivatives and pharmaceutical compositions containing the same - Google Patents
Pyrimidine derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL172937A0 IL172937A0 IL172937A IL17293706A IL172937A0 IL 172937 A0 IL172937 A0 IL 172937A0 IL 172937 A IL172937 A IL 172937A IL 17293706 A IL17293706 A IL 17293706A IL 172937 A0 IL172937 A0 IL 172937A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436203P | 2003-07-02 | 2003-07-02 | |
| US50020003P | 2003-09-04 | 2003-09-04 | |
| PCT/US2004/021440 WO2005003099A2 (en) | 2003-07-02 | 2004-07-02 | Pyrimidines useful as modulators of voltage-gated ion channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL172937A0 true IL172937A0 (en) | 2006-06-11 |
Family
ID=33567720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL172937A IL172937A0 (en) | 2003-07-02 | 2006-01-02 | Pyrimidine derivatives and pharmaceutical compositions containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7816529B2 (enExample) |
| EP (1) | EP1638955A2 (enExample) |
| JP (1) | JP2007521287A (enExample) |
| KR (1) | KR20060032190A (enExample) |
| AR (1) | AR045010A1 (enExample) |
| AU (1) | AU2004253962A1 (enExample) |
| CA (1) | CA2531061A1 (enExample) |
| IL (1) | IL172937A0 (enExample) |
| MX (1) | MXPA06000051A (enExample) |
| NO (1) | NO20060518L (enExample) |
| PE (1) | PE20051029A1 (enExample) |
| RU (1) | RU2006102955A (enExample) |
| TW (1) | TW200519094A (enExample) |
| WO (1) | WO2005003099A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| EP1863796A1 (en) * | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| WO2006119451A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| WO2006119390A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| EP1904491A2 (en) * | 2005-05-31 | 2008-04-02 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| EP2024333A2 (en) | 2006-04-26 | 2009-02-18 | Cancer Research Technology Limited | Amino-ethyl-amino-aryl (aeaa) compounds and their use |
| MX2008015908A (es) * | 2006-06-12 | 2009-01-28 | Vertex Pharma | Tienopirimidinas utiles como moduladores de canales de iones. |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| HUE036704T2 (hu) | 2007-05-22 | 2018-07-30 | Wyeth Llc | Továbbfejlesztett eljárás hidrazidok elõállítására |
| JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| NZ584471A (en) * | 2007-10-11 | 2012-01-12 | Glaxosmithkline Llc | Triazine cyclohexane carboxamide compounds and their use |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| JP2011510998A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2009097475A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| WO2009097474A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| US20090198057A1 (en) * | 2008-02-05 | 2009-08-06 | Pu-Ping Lu | Certain Chemical Entities, Compositions, and Methods |
| AP3272A (en) | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| AR075196A1 (es) | 2009-02-03 | 2011-03-16 | Otsuka Pharma Co Ltd | Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| PE20131377A1 (es) * | 2010-09-13 | 2013-11-30 | Novartis Ag | Triazina-oxadiazoles |
| CA2840883C (en) * | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| ES2730112T3 (es) | 2015-03-09 | 2019-11-08 | Bristol Myers Squibb Co | Lactamas como inhibidores de ROCK |
| GB201721751D0 (en) * | 2017-12-22 | 2018-02-07 | Adorx Therapeutics Ltd | Compounds |
| EP4320103A1 (en) * | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| US12030866B2 (en) | 2021-12-23 | 2024-07-09 | Springworks Therapeutics, Inc. | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD |
| WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| EP4532494A1 (en) | 2022-05-25 | 2025-04-09 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| AU2024234154A1 (en) | 2023-03-15 | 2025-09-25 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB901749A (en) | 1957-12-06 | 1962-07-25 | Ciba Ltd | New 2-substituted pyrimidines |
| US3040047A (en) | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| US3850928A (en) * | 1969-11-04 | 1974-11-26 | American Home Prod | Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids |
| US3850931A (en) | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| US3759922A (en) | 1971-06-25 | 1973-09-18 | American Home Prod | Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates |
| US3860596A (en) | 1972-08-31 | 1975-01-14 | American Home Prod | 2-aryl-4-substituted-amino-5-pyrimidyl derivatives |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| FR2263750A1 (en) | 1974-03-12 | 1975-10-10 | Delalande Sa | N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc. |
| FR2281117A2 (fr) * | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
| JPS6044303B2 (ja) * | 1975-02-25 | 1985-10-02 | 大日本製薬株式会社 | ２−環状アミノ−４−アミノピリミジン誘導体の製造法 |
| US4959368A (en) * | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| US20020183335A1 (en) * | 2001-02-20 | 2002-12-05 | Piyasena Hewawasam | 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| AU2003229305A1 (en) * | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| WO2006119451A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
-
2004
- 2004-07-02 EP EP04777512A patent/EP1638955A2/en not_active Withdrawn
- 2004-07-02 MX MXPA06000051A patent/MXPA06000051A/es unknown
- 2004-07-02 PE PE20050002102004000638A patent/PE20051029A1/es not_active Application Discontinuation
- 2004-07-02 RU RU2006102955/04A patent/RU2006102955A/ru not_active Application Discontinuation
- 2004-07-02 AU AU2004253962A patent/AU2004253962A1/en not_active Abandoned
- 2004-07-02 WO PCT/US2004/021440 patent/WO2005003099A2/en not_active Ceased
- 2004-07-02 JP JP2006517847A patent/JP2007521287A/ja not_active Withdrawn
- 2004-07-02 US US10/884,865 patent/US7816529B2/en not_active Expired - Fee Related
- 2004-07-02 KR KR1020067000095A patent/KR20060032190A/ko not_active Ceased
- 2004-07-02 TW TW093120064A patent/TW200519094A/zh unknown
- 2004-07-02 CA CA002531061A patent/CA2531061A1/en not_active Abandoned
- 2004-07-02 AR ARP040102352A patent/AR045010A1/es unknown
-
2006
- 2006-01-02 IL IL172937A patent/IL172937A0/en unknown
- 2006-02-01 NO NO20060518A patent/NO20060518L/no not_active Application Discontinuation
-
2010
- 2010-09-08 US US12/877,793 patent/US8324220B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7816529B2 (en) | 2010-10-19 |
| WO2005003099A3 (en) | 2005-05-12 |
| WO2005003099A2 (en) | 2005-01-13 |
| US8324220B2 (en) | 2012-12-04 |
| AU2004253962A1 (en) | 2005-01-13 |
| TW200519094A (en) | 2005-06-16 |
| CA2531061A1 (en) | 2005-01-13 |
| JP2007521287A (ja) | 2007-08-02 |
| KR20060032190A (ko) | 2006-04-14 |
| NO20060518L (no) | 2006-03-07 |
| PE20051029A1 (es) | 2005-12-07 |
| EP1638955A2 (en) | 2006-03-29 |
| MXPA06000051A (es) | 2006-03-21 |
| US20110003814A1 (en) | 2011-01-06 |
| RU2006102955A (ru) | 2007-08-20 |
| US20050049247A1 (en) | 2005-03-03 |
| AR045010A1 (es) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL172937A0 (en) | Pyrimidine derivatives and pharmaceutical compositions containing the same | |
| IL173602A0 (en) | Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same | |
| IL173627A0 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same | |
| IL173051A0 (en) | N-glucoside derivatives and pharmaceutical compositions containing the same | |
| IL162548A0 (en) | 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same | |
| IL171997A0 (en) | Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same | |
| IL175214A0 (en) | 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same | |
| IL166482A0 (en) | Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same | |
| IL241211A0 (en) | History of maytansinoid and pharmaceutical preparations containing them | |
| IL174128A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL166232A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
| IL206831A0 (en) | Glucopyranosyl derivatives and pharmaceutical compositions containing the same | |
| IL164209A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL164987A (en) | Proline derivatives and pharmaceutical compositions containing the same | |
| IL166620A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL164455A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL172159A0 (en) | 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same | |
| IL183583A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
| IL175252A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| IL178297A0 (en) | Hydrazide derivatives and pharmaceutical compositions containing the same | |
| IL221323A0 (en) | 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same | |
| IL176005A0 (en) | 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same | |
| IL182664A0 (en) | Triazole derivatives and pharmaceutical compositions containing the same | |
| IL177168A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
| IL166512A0 (en) | Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same |